Abstract: The invention provides a method of treating benzodiazepine-resistant status epilepticus in a subject having been exposed to a nerve agent inducing the status epilepticus.

Abstract: Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and/or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided are uses of these and other acyl-urea containing compounds in the treatment of neurological diseases and disorders.

Abstract: Amide derivatives of valproic acid are provided along their use in the treatment of epilepsy.

Abstract: Novel Alpha-halo- and Alpha-alkyl-cyclopropylcarboxy compounds, and uses of these and related compounds in the treatment of a variety of neurological diseases and disorders, and particularly epilepsy, are provided.

Abstract: The invention relates to the use of valnoctamide (VCD) for the treatment of bipolar disorder and in particular for the treatment of the manic phase of the bipolar disorder.

Abstract: The present invention concerns a family of sulfanilamide derivatives of formula (I) as anticonvulsant agents, where R is selected from optionally substituted C4-C9 alkyl, optionally substituted C6-C10 aryl, optionally substituted C6-C10 alkylenearyl and optionally substituted C5-C10heteroaryl; R2 is selected from —H and optionally substituted C1-C6 alkyl; each of R3 and R4, independently of each other, is selected from —H, optionally substituted C1-C6 alkyl, optionally substituted C6-C10 aryl and optionally substituted C5-C10 heteroaryl; n is 0, 1, 2, 3 or 4. The derivatives have been prepared and their anticonvulsant profile was evaluated for the control of epileptic seizures.

Abstract: Amide derivatives of valproic acid are provided along their use in the treatment of epilepsy.

Abstract: Novel acyl-urea containing compounds, processes of preparing same, compositions containing same and uses thereof in the treatment of neurological diseases and disorders such as epilepsy, neuropathic pain, bipolar disorder, status epilepticus, chemically-induced convulsions and/or seizure disorders, febrile convulsions conditions, metabolic disturbances and a sustenance withdrawal conditions, are provided. Also provided are uses of these and other acyl-urea containing compounds in the treatment of neurological diseases and disorders.

Abstract: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.

Abstract: Novel Alpha-halo- and Alpha-alkyl-cyclopropylcarboxy compounds, and uses of these and related compounds in the treatment of a variety of neurological diseases and disorders, and particularly epilepsy, are provided.

Abstract: The invention relates to the use of valnoctamide (VCD) for the treatment of bipolar disorder and in particular for the treatment of the manic phase of the bipolar disorder.

Abstract: The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a pharmaceutical composition comprising the compounds for treating a psychiatric disorder. A method for treating a psychiatric disorder preferably a bipolar disorder and a method for inhibiting an enzyme having MIP synthase activity is provided.

Abstract: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.

Abstract: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.

Abstract: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.

Abstract: The invention relates to new 2,2,3,3-tetramethylcyclopropane carboxamide derivative compounds, pharmaceutical compositions thereof and uses thereof for treating psychotic disorders, neurodegenerative diseases, epilepsy and pain.

Abstract: The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a pharmaceutical composition comprising the compounds for treating a psychiatric disorder. A method for treating a psychiatric disorder preferably a bipolar disorder and a method for inhibiting an enzyme having MIP synthase activity is provided.

Abstract: The invention relates to new 2,2,3,3-tetramethylcyclopropane carboxamide derivative compounds, pharmaceutical compositions thereof and uses thereof for treating psychotic disorders, neurodegenerative diseases, epilepsy and pain.

Abstract: The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided.

Abstract: The present invention relates to racemic propylisopropyl acetic acid and propylisopropyl acetamide and their isomers in their racemic and stereospecific forms, for use in treatment of neurological and psychotic disorders, and affective disorders and to treat pain, headaches and migraines. The isomers are of the compound formula I R1 is a methyl or ethyl group; R2 is H, methyl or an ethyl group; R3 is ethyl or a propyl group; and R4 is a hydroxyl or amide group, and the total number of carbon atoms in said compound is 8, provided that when R1 is a methyl group and R4 is an amide group, R2 and R3 are not ethyl, further provided that when R1 is an ethyl and R4 a hydroxyl group, only stereoisomers of the compound are referred to. The present invention further relates to a method for the stereoselective synthesis of the 2R stereoisomer of PID and PIA.